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Here in, we report the cytotoxicity of both rhodium and iridium 
functionalised Cp* analogues of the [Cp*MCl2]2 dimers. The 
functionalised dimers contain a hydroxy tethered arm of differing 
carbon length. These show promising IC50 values when tested 
against HT-29, A2780 and cisplatin-resistant A2780cis human 
cancer cell lines, with the cytotoxicity improving proportionally 
with an increase in carbon tether length of the Cp* ring. The most 
promising results are seen for the 14-carbon Cp* tethered 
rhodium (2d) and iridium (3b) complexes, which show up to a 24-
fold increase in IC50 compared to the unfunctionalised [Cp*MCl2]2 
dimer. All complexes were potent inhibitors of purified 
thioredoxin reductase suggesting that disruption of cellular anti-
oxidant function is one potential mechanism of action. 
In a search for less toxic and more potent alternatives to 
cisplatin, organometallic complexes have shown promising 
activity as anti-cancer agents.
1-4
 There are relatively few 
reported studies on the anti-cancer activity of rhodium and 
iridium Cp* complexes.
5-17
 Sadler et al. reported that for 
complexes with the general structure [Cp
‡
Ir(XY)Cl]
0/+
, where 
Cp
‡ 
is either Cp* or arene-functionalised Cp* ligands. Their 
potency towards A2780 human ovarian cancer cells increases 
with an increase in aryl substitution on the cyclopentadienyl 
ligand.
17
 Recently we demonstrated the use of various iridium 
Cp* piano stool complexes with promising activity for HT-29 
and MCF-7 cell lines, where [Cp*IrCl2]2 was inactive.
16
 
Therefore, breaking up the rhodium and iridium dihalide Cp* 
dimers with different bidentate ligands led to the development 
of complexes which show high in vitro cytotoxic activity against 
tumour cell lines.
5-19
 
 Where tested, studies have reported negligible activities of 
the starting dimers, i.e. [Cp*MCl2]2 (M = Rh or Ir)
16
 and there 
have been no previously reported examples of group 9 
dihalide functionalised Cp* dimers demonstrating cytotoxic 
behaviour. We are interested in the potential of converting 
these inactive dimers [Cp*MCl2]2 (M = Rh or Ir) to active 
cytotoxic agents through modifications of the Cp* ligand. 
Herein, we report the synthesis of ten complexes and a 
discussion of five new crystal structures of the type, [Cp
‡
MCl2]2 
(M = Rh or Ir). These complexes have also been evaluated for 
their cytotoxic activity in vitro against three tumour cell lines. 
Previous data has shown that the monomers were cytotoxic 
and therefore these dimers were tested in the hope to deliver 
two metal centres to the cancerous cells, potentially increasing 
the potency of the complex by up to 2-fold. To allow 
comparisons to be made between monomer and dimer, we 
have explored the effects of adding monodentate pyridine 
ligands and bidentate picolinamide ligands to both of the 
functionalised Cp
‡
 iridium and rhodium dimers. 
 Complexes 1b, 1d, 2b, 2d, 3a and 3b have been previously 
reported for their catalytic potential.
20-22 We investigated the 
immobilisation of these complexes onto Wang resin for use as 
recyclable transfer hydrogenation catalysts.
21
 In the hope to 
maximise the amount of metal that can reach the cancerous 
cells and to increase the drugs potency, the library of dimers 
has been tested against human colorectal adenocarcinoma 
(HT-29), human ovarian carcinoma (A2780) and cisplatin-
resistant human ovarian carcinoma (A2780cis). Due to the 
ability of the cyclopentadienyl hydroxyl-substituent to bind 
well to solid supports and with the previous evidence we have 
of the Cp* ligand binding to a metal centre,
23
 it is proposed 
that this alcohol could provide stability to the metal centre if 
the dimer breaks apart during its interaction with cells. The 
preparation of the dimeric complexes 2a-2d, 3a and 3b are 
shown in Scheme 1. The addition of monodentate pyridine and 
bidentate picolinamide ligands to the dimers, gave complexes 
4a, 4b, 5a and 5b. These were synthesised by a reaction of 3a 
or 3b with the corresponding ligand, as shown in Scheme 2. All 
of the complexes were characterised by 
1
H and 
13
C{
1
H} NMR 
spectroscopy, mass spectrometry and the novel complexes by 
elemental analysis. 
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Scheme 1 Formation of alcohol functionalised Cp‡ rhodium dimers 2a-2d and 
iridium dimers 3a-b. 
Scheme 2 Formation of alcohol functionalised Cp* rhodium and iridium pyridine 
and picolinamide complexes 4a. 4b. 5a and 5b. 
Single crystals of 2a and 2c were obtained by layer diffusion of 
hexane into a dichloromethane solution and vapour diffusion 
from dichloromethane/pentane solvent system respectively. 
The alcohol chain in 2c showed disorder, with four of the 
carbons equally occupied over two positions each (Figure S2). 
The rhodium and iridium pyridine complexes, 4a and 4b, were 
recrystallised from vapour diffusion of dichloromethane/ 
diisopropylether and chloroform/pentane solvent systems 
respectively. Complex 4b could not be solved to a publishable 
quality, however, it clearly shows the connectivity of iridium to 
a pyridine ligand, two chloride ligands and a 5 carbon 
functionalised Cp
‡
 ligand. The picolinamide complexes, 5a and 
5b, were crystallised using slow diffusion from a methanolic 
solution and layer diffusion from a dichloromethane/hexane 
solvent system respectively.  
 The complexes were obtained as orange-red single crystals 
and solutions were performed in either monoclinic (2a, 2c, 5a), 
triclinic (4a), or orthorhombic (5b) space groups. Selected 
bond lengths (Å) are presented in Table 1 and are in the range 
expected for these structures. All of the angles around the 
metal centre show the geometry expected for pseudo 
octahedral complexes which is common for these “piano-
stool” structures (Tables S1-2, Supplementary Information). 
The angles between the metal and bidentate ligands are in the 
range 77-91°, with the remaining three coordination sites  
Bond Lengths (Å) M(1)-Cl(1) M(1)-X M(1)-Y M(1)-Cg 
2a  
(X=Cl(2), Y=Cl(2’))
 2.4341(7) 2.4857(6) 2.4775(6) 1.774 
2c  
(X=Cl(2), Y=N(1)) 
 2.4353(8) 2.4693(8) 2.4776(9) 1.769 
4a  
(X=Cl(2), Y=N) 
2.4502(5) 2.4393(5) 2.150(1) 1.789 
5a  
(X=N(1), Y=N(2)) 
2.4416(8)/ 
2.4452(8) 
2.121(3)/ 
2.127(3) 
2.114(2)/ 
2.111(2) 
1.8091/ 
1.812 
5b  
(X=N(1), Y=N(2)) 
2.451(2) 2.136(5) 2.125(4) 1.823 
Table 1 Selected bond lengths () for complexes 2a, 2c, 4a, 5a and 5b 
 
occupied by the functionalised Cp
‡
 ligand and the angles 
observed for their centroids (Cg) to the chloride or ligands 
ranges between 125-134°. Molecular structures for complexes 
2a, 2c, 4a, 5a and 5b are shown in Figure 1. 
 The cytotoxic activities of complexes 2b-2d, 3a and 3b 
along with [Cp*RhCl2]2, [Cp*IrCl2]2 and cisplatin, were tested 
against HT-29, A2780 and A2780cis cell lines. The IC50 values 
(M) ± Standard Deviation are presented in Table 2. The 
potency of the monomeric pyridine complexes, 4a and 4b, 
were assessed against HT-29 cells and the picolinamide 
complexes, 5a and 5b, were assessed against A2780 cells. The 
pyridine complexes were less active than their dimeric 
precursors, 2b and 3a, with a 3-fold decrease in activity 
observed against HT-29 between 2b (30 ± 1 M) and 4b (92 ± 1 
M). Against A2780, the iridium picolinamide complex, 5b 
(52.5 ± 0.8 M), was also less active than its starting dimer, 3a 
(23.2 ± 0.8 M) with a 2.2-fold decrease in activity observed. 
The dimeric species, except for the anomalous result of 2b 
against A2780cis, upon replacing a Cp* methyl group with a 
longer aliphatic chain alcohol substituent, an increase in 
cytotoxicity is observed against all cell lines. The cytoxicity 
improves upon increasing the functionalisation of the Cp
‡
 
ligand, i.e. a longer alcohol chain decreases the complex’s IC50 
value and is therefore more potent. These results give the 
indication that the chain length of the Cp
‡
 could be a feature 
required for increased potency. 
 Both the rhodium and iridium complex 2d or 3b are the 
most potent of the dimers, with values comparable to 
cisplatin. Complex 2d is the first example of a cytotoxic 
functionalised Cp
‡
 rhodium complex. Previous rhodium Cp* 
complexes with reported cytotoxic activity have contained 
bidentate ligands that were designed to intercalate with 
DNA.
11, 18
 This rhodium 14-carbon tether dimer 2d (3.9 ± 0.1 
M), shows a 24-fold increase in IC50 against A2780 when 
compared to the unsubstituted dimer, [Cp*RhCl2]2 (95.0 ± 2.0 
M). The iridium complex 3a, with a 5 carbon chain, is 
significantly more active than its rhodium analogue 2b, most 
noticeably against the cisplatin-resistant A2780cis line with an 
IC50 of 28.4 ± 0.6 µM compared to 127.0 ± 6.0 μM. Against the 
A2780cis line, complexes 2d (4.9 ± 0.2 μM) and 3b (5.3 ± 0.1 
μM) have a 2-fold increase in active when compared to 
cisplatin (11.1 ± 0.6 μM), showing these complexes potential 
to circumvent cisplatin-resistance in cells. 
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Figure 1 Molecular structures of 2a, 2c, 4a, 5a and 5b. Hydrogen atoms are omitted for clarity and displacement ellipsoids are at the 50% probability level. 
 
 IC50 (M) ± SD 
Complex HT-29  A2780 A2780cis  
cisplatin 2.5 ± 0.1 0.95 ± 0.05 11.1 ± 0.6 
[RhCp*Cl2]2 141.0 ± 2.0 95.0 ± 2.0 90.0 ± 2.0 
[IrCp*Cl2]2 92.0 ± 4.0 30.9 ± 0.4 43.0 ± 3.0 
2b 123.0 ± 2.0 85.0 ± 7.0 127.0 ± 6.0 
2c 13.0 ± 0.2 6.2 ± 0.3 10.8 ± 0.7 
2d 12.7 ± 0.4 3.9 ± 0.1 4.9 ± 0.2 
3a 30.0 ± 1.0 23.2 ± 0.8 28.4 ± 0.6 
3b 10.6 ± 0.8 5.2 ± 0.2 5.3 ± 0.1 
4a 132.0 ± 2.0 - - 
4b 92.0 ± 1.0 - - 
5a - 85.0 ± 4 - 
5b - 52.5 ± 0.8 - 
 Table 1 IC50 (mM) values ± SD (standard deviation) from a 5 day MTT assay for complexes 2ab-d, 3a-b, 4a-b and-5a-b along with cisplatin, [IrCp*Cl2]2 and [RhCp*Cl2]2 for 
reference. (-) indicates no data is available 
  The in vitro MTT assay for determining chemosensitivity is 
a useful indication of drugs cytotoxicity but it provides little 
information as to individual drugs’ mode or modes of action. 
To gain a preliminary insight into this, the effects of the 
complexes on thioredoxin reductase activity were assessed. 
Thioredoxin reductase (Trx-R) is one of the key anti-oxidant 
enzymes in the cell, is commonly over expressed in tumours 
and can promote tumour growth and progression.
24
 We have 
previously reported a range of iridium picolinamide complexes 
that inhibit Trx-R, with IC50 values in the nanomolar range.
19, 25
 
This prompted us to investigate whether these novel 
complexes 2b, 2c, 2d, 3a and 3b reported here are also able to 
inhibit Trx-R activity. Significantly, all the active rhodium and 
iridium functionalised Cp
‡
 dimers were found to be potent Trx-
R inhibitors with IC50 values in the nanomolar or low 
micromolar range (Table 3 and Figure S1). 
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Complex IC50 (nM) ± SD 
2b 510 ± 59 
2c 398 ± 71 
2d 552 ± 34 
3a 217 ± 50 
3b 2098 ± 410 
Table 3. Thioredoxin reductase 1 (Trx-R) IC50 values (nM) ± SD for complexes 2b-d and 
3a-b. 
 
Complexes 2b and 2c are the most potent when assessing the 
chemosensitivity studies, however, they are not the most 
potent inhibitors of Trx-R. In fact, the least chemosensitive 
complex 3a is the most potent Trx-R inhibitor, with an IC50 
value of 217 ± 50 nM. These results show that Trx-R inhibition 
may contribute to the mode of action and the anti-cancer 
activity of some or all of our novel complexes; although it is 
likely that additional mechanisms may also be important and 
future studies will aim to explore this further. 
Conclusions 
We have extended our library of complexes of the type 
[Cp
‡
MCl2]2 where M = Rh/Ir and Cp
‡
 = C5(CH3)4(CH2)nOH, and 
have evaulated the complexes’ in vitro activities against HT-29, 
A2780 and A2780cis cell lines. In general, the anti-cancer 
activity improves upon increasing the chain length between 
the Cp ring and the OH, with the most promising IC50 values 
seen for the 14-carbon length tethered dimers. The most 
significant result was that of the rhodium 14-carbon tether 
dimer 2d (3.9 ± 0.1 M), in which a 24-fold increase in IC50 was 
observed when compared to the unsubstituted dimer, 
[Cp*RhCl2]2 (95.0 ± 2.0 M). This is the first example of a 
cytotoxic functionalised Cp
‡
 rhodium complex. The mechanism 
of action of organometallic complexes is generally complex but 
here we demonstrate that one potential mechanism involves 
inhibition of, thioredoxin reductase (Trx-R) activity. In a cell 
free assay, complexes 2b-d and 3a inhibited Trx-R activity with 
IC50 values in the nanomolar range. Whilst the active 
complexes 2b-d and 3a-b all show potent inhibitory activity 
against Trx-R. There was no strict correlation with the 
differential cytotoxicity of the complexes suggesting that 
additional mechanisms might also contribute to the mode of 
action of these complexes. 
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